ESRRA and neoplasm: In conclusion, the present research unveiled that gemcitabine combined with XCT790 synergistically inhibited cell viability, proliferation, migration, invasion, EMT and tumor growth via triggering G0/G1 celluler cycle retardation and apoptotic activity via the suppression of ERRα and MEK/ERK pathway in PC.